Molecular Study of the Poly (ADP-ribose) Polymerase-1 Gene as a Promotor of Inflammation-Driven Colorectal Carcinoma

  • 0Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

|

|

Summary

This summary is machine-generated.

This study found higher expression of PARP1 and NF-κB genes in colorectal cancer (CRC) tissues, suggesting potential therapeutic targets. These markers show promise for CRC diagnosis and may complement existing biomarkers.

Area Of Science

  • Oncology
  • Molecular Biology
  • Cancer Research

Background

  • Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
  • Chronic inflammation is a known risk factor for CRC, but underlying mechanisms remain unclear.
  • Understanding inflammation's role in CRC pathogenesis is crucial for developing effective treatments.

Purpose Of The Study

  • To investigate the mRNA expression levels of PARP1 and NF-κB/p50 in colorectal cancer.
  • To elucidate the role of PARP1 and NF-κB in inflammation-driven CRC.
  • To define stage-specific expression patterns of PARP1 and NF-κB in CRC.

Main Methods

  • Analysis of 35 CRC tissue samples and 25 healthy controls.
  • Quantification of PARP1 and NF-κB/p50 mRNA using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
  • Assessment of gene expression correlation and diagnostic accuracy (AUC).

Main Results

  • PARP1 and NF-κB/p50 mRNA expression were significantly elevated in CRC tissues compared to controls.
  • A positive correlation was observed between PARP1 and NF-κB/p50 mRNA levels, with PARP1 explaining 14.5% of the variation in NF-κB/p50.
  • Both markers demonstrated high diagnostic accuracy for CRC (AUC=0.905 for PARP1, AUC=0.956 for NF-κB/p50).

Conclusions

  • Overexpression of PARP1 and NF-κB suggests their involvement in CRC pathogenesis.
  • PARP1 inhibitors and anti-inflammatory drugs may hold therapeutic potential for CRC.
  • PARP1 and NF-κB warrant further investigation as diagnostic and prognostic markers for CRC.